Andrew Kruegel

Company: Gilgamesh Pharmaceutical

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: Evaluating the Current Ability for Preclinical Models & Biomarkers to Translate Psychiatric Programs into the Clinic 9:30 am

Critically analyzing animal models for accelerating translational development of psychedelic and non-psychedelic compounds Deciphering the most promising preclinical systems for assessing therapeutic durability Exploring the advantages and limitations of in vitro models for investigating potential drugs to target mental health disordersRead more

day: Conference Day Two

Panel Discussion: Reviewing the Current Therapeutic Landscape & Pipeline Advances in Neuropsychiatry 9:00 am

Evaluating the latest advancements in psychedelic and non-psychedelic therapeutic development Are the ‘mind altering’ effects of psychedelics necessary for therapeutic action? Exploring new potential treatment options for neuropsychiatric disordersRead more

day: Conference Day One